clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Bazzoli F et al. What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? 1999 Eur J Gastroenterol Hepatol pmid:10503822
Mégraud F Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. 1999 Eur J Gastroenterol Hepatol pmid:10503821
Spiller RC Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? 1999 Eur J Gastroenterol Hepatol pmid:10503819
Unge P The OAC and OMC options. 1999 Eur J Gastroenterol Hepatol pmid:10503817
Gómez G et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. 1999 Transplant. Proc. pmid:10500563
Landesman KA et al. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. 1999 Conn Med pmid:10500341
Zgoulli S et al. Microencapsulation of erythromycin and clarithromycin using a spray-drying technique. 1999 Sep-Oct J Microencapsul pmid:10499837
Ellenrieder V et al. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. 1999 Scand. J. Gastroenterol. pmid:10499474
Hirsh DC and Jang SS Antimicrobial susceptibility of Nocardia nova isolated from five cats with nocardiosis. 1999 J. Am. Vet. Med. Assoc. pmid:10496134
Osato MS et al. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. 1999 Int. J. Antimicrob. Agents pmid:10493611
Moore PA Dental therapeutic indications for the newer long-acting macrolide antibiotics. 1999 J Am Dent Assoc pmid:10492541
Gutiérrez-Cabano CA and Raynald AC Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats. 1999 Dig. Dis. Sci. pmid:10492159
Rodríguez Téllez M et al. Morphometric estimation of acid output in duodenal ulcer associated with Helicobacter pylori infection. 1999 Rev Esp Enferm Dig pmid:10491487
Tyagi AK et al. An unreported side effect of topical clarithromycin when used successfully to treat Mycobacterium avium-intracellulare keratitis. 1999 Cornea pmid:10487437
Matsuoka M et al. Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. 1999 Gut pmid:10486356
Klapper SR and Patrinely JR Periocular atypical mycobacterial infections. 1999 Ophthalmology pmid:10485521
Gidoh M [The control leprous peripheral neuropathy and chemotherapy]. 1999 Nihon Hansenbyo Gakkai Zasshi pmid:10481449
Sato K et al. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines]. 1999 Kekkaku pmid:10481412
Gómez Cubillos C et al. [Can macrolide treatment delay the diagnosis of tuberculosis?]. 1999 An Med Interna pmid:10481348
Geiderman JM Central nervous system disturbances following clarithromycin ingestion. 1999 Clin. Infect. Dis. pmid:10476775
Mikamo H et al. Adequate macrolide treatment schedules for uterine cervicitis caused by Chlamydia trachomatis. 1999 Sep-Oct Chemotherapy pmid:10473928
Tanaka E et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. 1999 Am. J. Respir. Crit. Care Med. pmid:10471610
Bui KQ et al. Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. 1999 Antimicrob. Agents Chemother. pmid:10471584
Kamada T et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. 1999 Helicobacter pmid:10469195
Catalano F et al. Comparative treatment of Helicobacter pylori-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. 1999 Helicobacter pmid:10469192
Sung JJ et al. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. 1999 Aliment. Pharmacol. Ther. pmid:10468684
Paré P et al. Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10468683
Gschwantler M et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. 1999 Aliment. Pharmacol. Ther. pmid:10468682
Gooderham MJ et al. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. 1999 Jul-Aug Ann Pharmacother pmid:10466907
Sendi PP et al. Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. 1999 J Eval Clin Pract pmid:10461580
Boyanova L et al. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. 1999 Diagn. Microbiol. Infect. Dis. pmid:10459482
Labenz J and Stolte M [Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. 1999 Z Gastroenterol pmid:10458014
Härtig G et al. [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. 1999 Psychiatr Prax pmid:10457975
Pandita D and Carson PJ Thyroid abscess caused by Mycobacterium chelonae. 1999 Clin. Infect. Dis. pmid:10452671
Gordin FM et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. 1999 Clin. Infect. Dis. pmid:10452638
Anzueto A et al. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. 1999 Clin. Infect. Dis. pmid:10451195
Enroth H et al. Occurence of resistance mutation and clonal expansion in Helicobacter pylori multiple-strain infection: a potential risk in clarithromycin-based therapy. 1999 Clin. Infect. Dis. pmid:10451171
Hewitt RG et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. 1999 AIDS pmid:10449290
Ali' A et al. A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. 1999 Am. J. Gastroenterol. pmid:10445583
Bazzoli F My approach to Helicobacter pylori eradication. 1999 Eur J Gastroenterol Hepatol pmid:10443911
Shimada N et al. [A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin]. 1999 Nihon Jinzo Gakkai Shi pmid:10441997
Lipsky BA et al. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin. 1999 Clin Ther pmid:10440620
Cohn DL et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. 1999 Clin. Infect. Dis. pmid:10433575
Schmitt H et al. Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin, and sparfloxacin. 1999 Clin. Infect. Dis. pmid:10433574
Baena Díez JM et al. [Are 5 days of omeprazole plus 2 antibiotics enough for eradication of H. pylori? Comments on sample size]. 1999 Rev Clin Esp pmid:10432821
Owen RJ et al. Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. 1999 Microb. Drug Resist. pmid:10432275
Kyzekova J and Mour J The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. 1999 May-Jun Hepatogastroenterology pmid:10430396
Credito KL et al. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. 1999 Antimicrob. Agents Chemother. pmid:10428930
Johnson MM et al. Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. 1999 Antimicrob. Agents Chemother. pmid:10428903
Grimm KJ Treatment of Helicobacter pylori infection in functional dyspepsia. 1999 J Fam Pract pmid:10428242